Colistin Dosing and Combination Therapy Guide
Recommended Dosing Regimen
For critically ill adults with normal renal function, administer a loading dose of 9 million IU (MU) of colistin methanesulfonate (CMS) followed by a maintenance dose of 4.5 MU every 12 hours 1. This loading dose is essential because without it, plasma colistin concentrations remain suboptimal for 2-3 days before reaching steady state 2.
Adult Dosing Algorithm
Loading Dose (all patients, including renal dysfunction):
Maintenance Dose (adjust based on creatinine clearance):
| CrCl (mL/min) | Maintenance Dose | Frequency |
|---|---|---|
| ≥80 | 4.5 MU | Every 12h |
| 50-79 | 2.5-3.8 mg/kg/day | Divided into 2 doses |
| 30-49 | 2.5 mg/kg | Once daily or divided into 2 doses |
| 10-29 | 1.5 mg/kg | Every 36 hours |
The maintenance dose can be calculated using: 2.5 mg × (1.5 × CrCl + 30) every 12 hours 1
Critical caveat: The FDA maximum daily dose is 5 mg/kg/day with normal renal function 3, but pharmacodynamic studies support higher dosing in critically ill patients 1. For obese patients, use ideal body weight for calculations 3.
Pediatric Dosing
Important limitation: These pediatric doses may be inadequate when the pathogen MIC is ≥1 mg/L or in patients with augmented renal clearance 1.
Administration Methods
Intravenous options:
- Intermittent: Inject half the daily dose over 3-5 minutes every 12 hours 3
- Continuous infusion: Inject half the daily dose over 3-5 minutes, then infuse the remaining half over 22-23 hours 3
Extended 4-hour infusions optimize pharmacokinetic/pharmacodynamic properties and may allow treatment of strains with MIC up to 8 mg/L 2.
Combination Therapy Evidence
The Controversy
The evidence for colistin combination therapy versus monotherapy is contradictory and remains controversial 1. Here's what the data shows:
Against combination therapy:
- A randomized controlled trial found colistin plus meropenem was NOT superior to colistin monotherapy for Pseudomonas or carbapenem-resistant Gram-negative bacteria, with 14-day mortality of 25% vs 31% (p=1.0) 1
- The OVERCOME trial (double-blind RCT) showed similar 28-day mortality: 46% with colistin monotherapy vs 42% with colistin-meropenem (p=0.5) 4
Supporting combination therapy:
- Other studies demonstrated polymyxin B combination therapy had lower mortality compared to monotherapy, even when the combined agent lacked in vitro activity 1
- Network meta-analysis for carbapenem-resistant Acinetobacter baumannii bacteremia showed colistin plus carbapenem had the highest SUCRA score (83.6) compared to colistin monotherapy (18.8) 1
Practical Recommendations for Combination Therapy
Despite the controversy, consider combination therapy in these situations:
First choice: Combine colistin with one or more agents to which the pathogen displays in vitro susceptibility 1
When no susceptible agent available: Combine colistin with a second or third non-susceptible agent (e.g., carbapenem) that has the lowest MIC 1
Specific combinations tested:
- Colistin + carbapenem: Most studied, particularly for carbapenem-resistant Enterobacteriaceae 1
- Colistin + tigecycline: SUCRA score 70.1 for mortality 1
- Colistin + rifampin: Three RCTs showed NO advantage over monotherapy for CRAB infections 4
- Colistin + fosfomycin: Limited data, always use in combination 2
- Colistin + vancomycin: Higher nephrotoxicity with no mortality benefit—avoid 4
For specific pathogens:
- Carbapenem-resistant K. pneumoniae: Combination with another active antibiotic (preferably meropenem/doripenem when MIC ≤8 mg/L) is recommended 5
- A. baumannii and P. aeruginosa: Monotherapy appears adequate 5
Critical Safety Monitoring
Nephrotoxicity
Acute kidney injury is the most important factor related to clinical failure and mortality with colistin 1.
Mandatory monitoring:
- Monitor renal function closely throughout therapy (Strong recommendation) 1
- Nephrotoxicity occurs in approximately 3.9-33% of patients 2, 6
- Risk is dose-dependent 3
- Reversible upon discontinuation 3
High-risk patients requiring extra caution:
Neurotoxicity
Neurological adverse effects include:
- Circumoral paresthesia or numbness 3
- Tingling or formication of extremities 3
- Generalized pruritus, vertigo, dizziness 3
- Slurring of speech 3
- Respiratory arrest (rare but reported) 3
- Apnea and neuromuscular blockade, especially with renal impairment 3
Patient counseling: Warn patients not to drive vehicles or use hazardous machinery during therapy 3. Dose reduction may alleviate symptoms without requiring discontinuation 3.
Pharmacokinetic Considerations
When Standard Dosing May Fail
Critical limitation: Patients with creatinine clearance ≥80 mL/min may not achieve adequate plasma concentrations (Css,avg ≥2 mg/L) even with maximum allowed daily doses of 360 mg colistin base activity 7. Target attainment was <40% in these patients 7.
For high MIC pathogens (≥1 mg/L):
- Standard regimens risk underexposure in patients with normal renal function 8, 6
- Consider off-label high-dose regimens to ensure adequate exposure 8
- When MIC ≥2 mg/L, no dosing regimen achieves ≥90% probability of target attainment 8
Renal Replacement Therapy
For patients on continuous renal replacement therapy (CRRT):
- Use the same loading dose (9 MU) 2
- Supplemental dosing achieves >80% target attainment 7
- Dose adjustments are necessary 3
For intermittent hemodialysis:
- On non-dialysis days, follow the algorithm for patients not on RRT 7
Key Pitfalls to Avoid
Skipping the loading dose: This is the most common error—plasma levels remain suboptimal for days without it 2
Using colistin monotherapy for high-burden infections: Front-loading strategies as part of combination therapy are essential for aggressive treatment 9
Inadequate dosing in augmented renal clearance: Critically ill patients with preserved or enhanced renal function often receive insufficient doses 1, 8
Ignoring MIC values: When MIC ≥1 mg/L, standard dosing is likely inadequate 8, 6
Combining with vancomycin: This increases nephrotoxicity without improving outcomes 4
Failing to adjust for obesity: Always use ideal body weight, not actual weight 3